Who
Kinney Horn
Chief Business Officer
Company insider
Files Form 4 as: Chief Business Officer, Immunome; Chief Business Officer, Olema Pharmaceuticals.
In numbers
- Trades disclosed
- 69
- Buys
- 0
- Sells
- 12
- Bought
- $0
- Sold
- $7.6M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 10 Jun 2020
- Last trade
- 4 Aug 2026
- Last filed
- 6 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Aug 2026filed 6 Aug 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Code M | $651K50,366 at $12.92 | filing |
| 4 Aug 2026filed 6 Aug 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Code M | $427K40,250 at $10.60 | filing |
| 4 Aug 2026filed 6 Aug 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Sold | $2.3M90,616 at $25.09 | filing |
| 4 Aug 2026filed 6 Aug 2026 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,366 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,250 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,366 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,250 at $0.00 | filing |
| 4 Aug 2026filed 6 Aug 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Code M | $651K50,366 at $12.92 | filing |
| 4 Aug 2026filed 6 Aug 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Code M | $427K40,250 at $10.60 | filing |
| 4 Aug 2026filed 6 Aug 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Sold | $2.3M90,616 at $25.09 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,500 at $0.00 | filing |
| 23 Jul 2026filed 27 Jul 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Code M | $14K1,092 at $12.92 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Sold | $27K1,092 at $25.00 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,092 at $0.00 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IMNM Immunomeoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,092 at $0.00 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Code M | $14K1,092 at $12.92 | filing |
| 7 Jul 2026filed 9 Jul 2026 | IMNM ImmunomeBiotechnology | SEC FORM 4 Sold | $27K1,092 at $25.00 | filing |
News
Arbutus Biopharma (NASDAQ:ABUS) vs. Immunome (NASDAQ:IMNM) Financial ComparisonIMNM · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Kinney Horn; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.